A
AdipoPharma
Biotech & Life Sciences · Strasbourg, France · Founded 2017
Development of a first-in-class drug for type 2 diabetes, targeting adipocyte cells to reverse insulin resistance MoreLess
AdipoPharma is a French biotechnology company that is developing a novel drug for the treatment of type 2 diabetes. The company's approach focuses on the role of adipocyte cells in the regulation of lipid biosynthesis and the management of lipids throughout the body. By targeting these cells, AdipoPharma aims to develop a therapy that can reverse insulin resistance, a key factor in the development of type 2 diabetes.
The company's business model is centered on the research and development of its lead drug candidate. AdipoPharma has successfully secured Series A funding, which will be used to advance its first-in-class compound into clinical trials. The company's target market includes individuals with type 2 diabetes and other metabolic diseases. As a biotechnology firm, its clients are investors and potential partners in the pharmaceutical industry for licensing or acquisition. The company's revenue will be generated through these partnerships and, eventually, from the sale of its approved drug.
Keywords: biotechnology, pharmaceuticals, type 2 diabetes, insulin resistance, adipocyte cells, drug development, clinical trials, metabolic diseases, therapeutic peptide, lipid biosynthesis
Company overview
AdipoPharma company information
The essential company record, classifications and operating signals in one place.
- Status
- Operational
- Founded
- 2017
- Headquarters
- Strasbourg, France
- Employees
- 7
- Open positions
- None listed
- Dealroom signal
- 76.7
Valuation & funding
AdipoPharma funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| EARLY VC✓Equity / VC | Nov 2024 | $0 | — | Okeanos · Sambrinvest · Newton BioCapital · Good Growth Capital | ↗ |
| SERIES A✓Equity / VC | Jan 2023 | — | — | Good Growth Capital · Newton BioCapital | ↗ |
| EARLY VC✓Equity / VC | Oct 2017 | $17M | $66M | Bpifrance | ↗ |
| SPINOUT✓Other financing | Jul 2017 | $0 | — | SATT Conectus · University of Strasbourg | ↗ |
Financials
Workforce over time
Available workforce history. Financial fields without reported data are omitted.
| Year | Employees |
|---|---|
| 2026 | 7 |
| 2025 | 7 |
| 2024 | 6 |
| 2023 | 5 |
Growth signals
AdipoPharma website traffic
Latest recorded traffic for AdipoPharma is 1.4K monthly website visits, up 44.3% over the last three months. AdipoPharma's team grew 0% over the past year.
Comparisons
AdipoPharma compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
| Company | Headquarters | Status | Employees | Total funding | Valuation |
|---|---|---|---|---|---|
 VAXXELVaxxel develops novel and proprietary live-attenuated vaccines candidate against respiratory infections |
Villeurbanne, France | Operational | 10 | $1.3M | $5.3M |
 Qubit PharmaceuticalsQuantum physics and AI-driven drug discovery platform |
Paris, France | Operational | |||
 DiogenXBeta-Cell recovery to counter diabetes |
Marseille, France | Operational | |||
 Aelis FarmaBiotech company conducting research and development on innovative signaling specific drugs |
Bordeaux, France | Operational | |||
 Seekyo TherapeuticsA privately-owned biotech company developing a Smart Chemotherapy, selective to tumours, safe for patients |
Saint-Maur-des-Fossés, France | Operational | |||
 MedinCellDevelops therapeutic solutions based on proprietary copolymers and a biocompatible solvent |
Jacou, France | Operational | |||
 CellectisDeveloping allogeneic CAR-T cells |
Paris, France | Operational | |||
 DBV TechnologiesEpicutaneous immunotherapy patch for treating food allergies. |
Châtillon, France | Operational |
Talent graph
AdipoPharma's talent
Source: Dealroom Talent Intelligence.
Global footprint
Where AdipoPharma has talent and traffic
team presence
In the news
Latest news about AdipoPharma
Recent press, funding announcements, and product moves mentioning AdipoPharma — open to read from the original sources.
Market sentiment
What the market is saying about AdipoPharma
An AI-synthesized read of the highest-engagement posts about AdipoPharma on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See AdipoPharma’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.